1-11 of 11
Wen-Jen Hwu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5086–5091.
https://doi.org/10.1158/1078-0432.CCR-20-0177
Published: 01 October 2020
View article titled, Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Open the PDF for Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B in another window
Includes: Supplementary data
Journal Articles

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 6098.
https://doi.org/10.1158/1078-0432.CCR-18-3340
Published: 03 December 2018
View article titled, Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Journal Articles

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (20): 4960–4967.
https://doi.org/10.1158/1078-0432.CCR-17-2386
Published: 15 October 2018
View article titled, Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

Marie-Andrée Forget, Cara Haymaker, Kenneth R. Hess, Yuzhong Jeff Meng, Caitlin Creasy, Tatiana Karpinets, Orenthial J. Fulbright, Jason Roszik, Scott E. Woodman, Young Uk Kim, Donastas Sakellariou-Thompson, Ankit Bhatta, Arely Wahl, Esteban Flores, Shawne T. Thorsen, René J. Tavera, Renjith Ramachandran, Audrey M. Gonzalez, Christopher L. Toth, Seth Wardell, Rahmatu Mansaray, Vruti Patel, Destiny Joy Carpio, Carol Vaughn, Chantell M. Farinas, Portia G. Velasquez, Wen-Jen Hwu, Sapna P. Patel, Michael A. Davies, Adi Diab, Isabella C. Glitza, Hussein Tawbi, Michael K. Wong, Suzanne Cain, Merrick I. Ross, Jeffrey E. Lee, Jeffrey E. Gershenwald, Anthony Lucci, Richard Royal, Janice N. Cormier, Jennifer A. Wargo, Laszlo G. Radvanyi, Carlos A. Torres-Cabala, Rameen Beroukhim, Patrick Hwu, Rodabe N. Amaria, Chantale Bernatchez
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4416–4428.
https://doi.org/10.1158/1078-0432.CCR-17-3649
Published: 14 September 2018
View article titled, Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
Open the PDF for Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome in another window
Includes: Supplementary data
Journal Articles

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1805–1815.
https://doi.org/10.1158/1078-0432.CCR-17-3436
Published: 12 April 2018
View article titled, Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Open the PDF for Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study in another window
Includes: Supplementary data
Journal Articles

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Laszlo G. Radvanyi, Chantale Bernatchez, Minying Zhang, Patricia S. Fox, Priscilla Miller, Jessica Chacon, Richard Wu, Gregory Lizee, Sandy Mahoney, Gladys Alvarado, Michelle Glass, Valen E. Johnson, John D. McMannis, Elizabeth Shpall, Victor Prieto, Nicholas Papadopoulos, Kevin Kim, Jade Homsi, Agop Bedikian, Wen-Jen Hwu, Sapna Patel, Merrick I. Ross, Jeffrey E. Lee, Jeffrey E. Gershenwald, Anthony Lucci, Richard Royal, Janice N. Cormier, Michael A. Davies, Rahmatu Mansaray, Orenthial J. Fulbright, Christopher Toth, Renjith Ramachandran, Seth Wardell, Audrey Gonzalez, Patrick Hwu
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (24): 6758–6770.
https://doi.org/10.1158/1078-0432.CCR-12-1177
Published: 16 December 2012
View article titled, Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
Open the PDF for Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Michael A. Davies, Patricia S. Fox, Nicholas E. Papadopoulos, Agop Y. Bedikian, Wen-Jen Hwu, Alexander J. Lazar, Victor G. Prieto, Kirk S. Culotta, Timothy L. Madden, Quanyun Xu, Sha Huang, Wanleng Deng, Chaan S. Ng, Sanjay Gupta, Wenbin Liu, Janet E. Dancey, John J. Wright, Roland L. Bassett, Patrick Hwu, Kevin B. Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1120–1128.
https://doi.org/10.1158/1078-0432.CCR-11-2436
Published: 14 February 2012
View article titled, Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
Open the PDF for Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy

Richard W. Joseph, Vijay R. Peddareddigari, Ping Liu, Priscilla W. Miller, Willem W. Overwijk, Nebiyou B. Bekele, Merrick I. Ross, Jeffrey E. Lee, Jeffrey E. Gershenwald, Anthony Lucci, Victor G. Prieto, John D. McMannis, Nicholas Papadopoulos, Kevin Kim, Jade Homsi, Agop Bedikian, Wen-Jen Hwu, Patrick Hwu, Laszlo G. Radvanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (14): 4882–4891.
https://doi.org/10.1158/1078-0432.CCR-10-2769
Published: 17 July 2011
View article titled, Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy
Open the PDF for Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy in another window
Journal Articles

Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside

Paul B. Chapman, Dianna Wu, Govind Ragupathi, Sharon Lu, Linda Williams, Wen-Jen Hwu, Diantha Johnson, Philip O. Livingston
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4717–4723.
https://doi.org/10.1158/1078-0432.CCR-04-0345
Published: 21 July 2004
View article titled, Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside
Open the PDF for Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside in another window
Journal Articles

Consistent Antibody Response against Ganglioside GD2 Induced in Patients with Melanoma by a GD2 Lactone-Keyhole Limpet Hemocyanin Conjugate Vaccine plus Immunological Adjuvant QS-21

Govind Ragupathi, Philip O. Livingston, Chandra Hood, John Gathuru, Susan E. Krown, Paul B. Chapman, Jedd D. Wolchok, Linda J. Williams, Roberta C. Oldfield, Wen-Jen Hwu
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5214–5220.
Published: 12 November 2003
View article titled, Consistent Antibody Response against Ganglioside GD2 Induced in Patients with Melanoma by a GD2 Lactone-Keyhole Limpet Hemocyanin Conjugate Vaccine plus Immunological Adjuvant QS-21
Open the PDF for Consistent Antibody Response against Ganglioside GD2 Induced in Patients with Melanoma by a GD2 Lactone-Keyhole Limpet Hemocyanin Conjugate Vaccine plus Immunological Adjuvant QS-21 in another window
Journal Articles

T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants

Susanne G. Schaed, Virginia M. Klimek, Katherine S. Panageas, Cristina M. Musselli, Leah Butterworth, Wen-Jen Hwu, Philip O. Livingston, Linda Williams, Jonathan J. Lewis, Alan N. Houghton, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (5): 967–972.
Published: 01 May 2002
View article titled, T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201<sup>+</sup> Melanoma Patients: <subtitle>Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants</subtitle>
Open the PDF for T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201<sup>+</sup> Melanoma Patients: <subtitle>Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants</subtitle> in another window